- Home
- ATNF vs APVO Comparison
ATNF vs APVO Comparison
Compare ATNF & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNF
- APVO
- Stock Information
- Founded
- ATNF 2016
- APVO 2016
- Country
- ATNF United States
- APVO United States
- Employees
- ATNF N/A
- APVO N/A
- Industry
- ATNF Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- ATNF Health Care
- APVO Health Care
- Exchange
- ATNF Nasdaq
- APVO Nasdaq
- Market Cap
- ATNF 3.8M
- APVO 4.1M
- IPO Year
- ATNF N/A
- APVO N/A
- Fundamental
- Price
- ATNF $1.05
- APVO $4.95
- Analyst Decision
- ATNF
- APVO Strong Buy
- Analyst Count
- ATNF 0
- APVO 1
- Target Price
- ATNF N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- ATNF 43.3K
- APVO 393.8K
- Earning Date
- ATNF 05-15-2025
- APVO 05-14-2025
- Dividend Yield
- ATNF N/A
- APVO N/A
- EPS Growth
- ATNF N/A
- APVO N/A
- EPS
- ATNF N/A
- APVO N/A
- Revenue
- ATNF N/A
- APVO N/A
- Revenue This Year
- ATNF N/A
- APVO N/A
- Revenue Next Year
- ATNF N/A
- APVO N/A
- P/E Ratio
- ATNF N/A
- APVO N/A
- Revenue Growth
- ATNF N/A
- APVO N/A
- 52 Week Low
- ATNF $0.66
- APVO $4.30
- 52 Week High
- ATNF $17.75
- APVO $658.60
- Technical
- Relative Strength Index (RSI)
- ATNF 49.77
- APVO 28.32
- Support Level
- ATNF $1.01
- APVO $4.30
- Resistance Level
- ATNF $1.10
- APVO $5.18
- Average True Range (ATR)
- ATNF 0.08
- APVO 1.22
- MACD
- ATNF -0.01
- APVO 0.72
- Stochastic Oscillator
- ATNF 35.29
- APVO 6.47
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp was formed as a clinical-stage biotechnology company, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis by employing research, and, where appropriate, combination therapy. In addition, it has acquired certain source code and intellectual property relating to the back-end technology platform to operate an online blockchain casino, and moving forward, it plans to focus the majority of its operations on the creation of the online blockchain casino, while looking to monetize certain prior development-stage therapeutic product candidates for unmet medical needs. It has one reportable operating segment, iGaming.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.